LinkedIn Logo

February 20-22, 2018

Boston, USA

Speakers

Expand/Collapse

Alexandre Akoulitchev
Chief Scientific Officer and Co-Founder
Oxford BioDynamics

Day Two

Thursday, February 22nd, 2018

13.30 | Multi-Center Biomarker Development for Diagnosis and Prognosis of Amyotrophic Lateral Sclerosis

14.30 | Session Q&A Panel

Alice Zhang
CEO
Verge Genomics

Brad Margus
Co-founder & CEO
Cerevance

Brendon Boot
Medical Director
Voyager Therapeutics

Damian Crowther
Director, R&D Neuroscience IMED Biotech Unit
AstraZeneca

Day One

Wednesday, February 21, 2018

09.30 | Session Q&A Panel

08.50 | Shedding Light on the Role of TREM2 in Alzheimer’s Disease

Douglas Bonhaus
CSO
Neuropore Therapeutics

Day Two

Thursday, February 22nd, 2018

16.20 | Session Q&A Panel

16.00 | Targeting Autophagic Protein Clearance Mechanisms for the Treatment of Neurodegenerative Disease

Douglas Galasko
Professor, Department of Neurosciences
University of California, San Diego

Day Two

Thursday, February 22nd, 2018

14.30 | Session Q&A Panel

14.10 | Biomarker Data in Cerebrospinal Fluid in Parkinson’s Disease: The PPMI Study

Holly Soares
Head Translational Neuroscience
AbbVie

Day Two

Thursday, February 22nd, 2018

14.30 | Session Q&A Panel

13.50 | Utility of Neurofilament Light Chain as a Translational Tool in Neurodegenerative Disorders

Jan Torleif Pedersen
Director, TBL Alzheimers Disease and Dementia
Neurodegeneration, H. Lundbeck A/S

Day Two

Thursday, February 22nd, 2018

09.30 | Session Q&A Panel

08.50 | Development of Phospo-Tau Antibodies Targeting Pathologic Forms of Tau

Jay Schneider
Professor, Pathology, Anatomy and Cell Biology, Director, Parkinson’s Disease Research Unit
Thomas Jefferson University

Day One

Wednesday, February 21, 2018

16.30 | Evaluating Translatability: Relevance of Rodent & Nonhuman Primate Preclinical Models of Cognitive Impairment to Clinical Drug Development

17.30 | Session Q&A Panel

Johan Luthman
Vice President, Neuroscience Business Group
Eisai Pharmaceuticals

Day Two

Thursday, February 22nd, 2018

12.00 | Session Q&A Panel

11.00 | Perspectives on Biomarker Applications Through Drug Development

Jonathan Brotchie
Co-Founder and Chairman
Atuka Inc.

Day One

Wednesday, February 21, 2018

17.30 | Session Q&A Panel

16.50 | Translational Value of Non-Human Primate Models of Motor Impairment and Disease Progression in Parkinson’s Disease

Jonathan Levenson
Senior Director, Preclinical Research & Development
Proclara Biosciences

Day Two

Thursday, February 22nd, 2018

16.20 | Session Q&A Panel

15.20 | Developing Preclinical Biomarkers of Proteopathic Seeds in Neurodegenerative Disease

Krzysztof Wicher
Principal Scientist and Group Leader
Ossianix

Larry Brown
Executive Vice President R&D, Chief Scientific Officer
Noveome Biotherapeutics

Laurent Bogdanik
Senior Study Director; Lead Scientist in Neurobiology
The Jackson Laboratory

 

Martin Tolar
Founder, President & CEO
Alzheon, Inc

Day Two

Thursday, February 22nd, 2018

09.30 | Session Q&A Panel

08.30 | The Amyloid Cascade Hypothesis: The Path Forward in Developing Targeted Therapies for Alzheimer’s Disease

Massimiliano Bianchi
General Manager & Scientific Director
Transpharmation Ltd

Day One

Wednesday, February 21, 2018

09.30 | Session Q&A Panel

09.10 | The Importance of Microtubular Proteins & Cytokines in Neuroplasticity & Neuroinflammation

Ottavio Vitolo
VP Clinical Development
Homology Medicines Inc

Workshop A

Tuesday, February 20

08.00 | Exploring the Application of Gene Editing in the Treatment of CNS Disorders

Patrice Garnier
CEO
Amabiotics

Workshop C

Tuesday, February 20

15.00 | The Gut-Brain Axis: The Microbiome as a Versatile Target for Neurodegenerative Disease

Ping Chiao
Senior Director
Biogen

Day Two

Thursday, February 22nd, 2018

12.00 | Session Q&A Panel

11.20 | Amyloid PET Imaging in Aducanumab Ph1b PRIME study

Richard Ransohoff
Previously VP & Senior Research Fellow Neuroimmunology (Biogen)
Harvard Medical School

Day One

Wednesday, February 21, 2018

09.30 | Session Q&A Panel

08.30 | (Re) Introduction to Microglia as Intrinsic Brain Cells

Richard Wade-Martins
Professor Molecular Neuroscience
University of Oxford

Richard Wyse
Director of Research & Development Research & Development
The Cure Parkinson's Trust

Day One

Wednesday, February 21, 2018

08.25 | Chairs Welcoming & Opening Remarks

Day Two

Thursday, February 22nd, 2018

08.25 | Chairs Opening Remarks

Rick Hiatt
President and CEO
Cerveau Technologies, Inc.

Day Two

Thursday, February 22nd, 2018

11.40 | Presentation to Be Confirmed

Robert C. Switzer
Founder & Scientific Director
NeuroScience Associates

Day One

Wednesday, February 21, 2018

16.00 | Presentation Title To Be Confirmed

S. Pablo Sardi
R&D Director
Sanofi-Genzyme

Day Two

Thursday, February 22nd, 2018

16.20 | Session Q&A Panel

15.40 | The Role of GBA in Lysosomal Function, Neuroprotection and Progression in Parkinson’s Disease

Samuel Hasson
Principal Investigator, Neuroscience
Pfizer

Workshop B

Tuesday, February 20

11.30 | The Promise & Challenge of Neuroimmune Therapeutics: Targets, Models, and the Science Behind the Innate Immune System’s Role in Neurodegenerative Disease

Susan Browne
Director
Teva Pharmaceuticals

Tamara Maes
CSO and VP
Oryzon Genomics S.A

Thomas Skøt Jensen
CEO & Co-founder
Intomics

Day Two

Thursday, February 22nd, 2018

09.10 | Precision Medicine in a Data-rich Era – Challenges and Successful Bioinformatics Approaches

09.30 | Session Q&A Panel

Nikolai Naryshkin
Executive Director, Biology – Genetic Disorders
PTC Therapeutics, Inc.

Speaker to be Confirmed

Cerveau Technologies

Day Two

Thursday, February 22nd, 2018

12.00 | Session Q&A Panel